Instead of a traditional IPO, Candid Therapeutics secured a NASDAQ listing and a massive capital infusion by merging with RallyBio. This reverse merger, coupled with a concurrent private investment, provides nearly $700 million in cash to fund operations through 2030, demonstrating a powerful alternative financing path to public markets.

While reverse mergers offer a faster route to public markets, they bypass the extensive investor meetings of a traditional IPO. This can result in a narrowly held story and weaker sell-side coverage, forcing companies to spend 6-12 months post-deal building the investor base they missed.

Albareo was ready to IPO with strong investor interest in summer 2015, but the market window slammed shut due to external events like the Martin Shkreli scandal. This forced the company into a creative reverse merger, a stark reminder that IPO timing is ultimately dictated by market sentiment beyond a company's control.

Reverse mergers are no longer a 'back door' listing method. Their acceptance by high-quality companies is driven by the concurrent PIPE financing, which recapitalizes the company and brings in a supportive, institutional shareholder base, mitigating the risk of inheriting a mismatched investor group.

While staying private can offer strategic advantages, particularly for future M&A, the biotech industry lacks a mature private growth capital market. Companies needing hundreds of millions for late-stage trials have no choice but to go public, unlike their tech counterparts.

Biotech firms are increasingly using reverse mergers paired with substantial PIPE financings ($200M+) as an alternative path to the public markets. This "IPO-esque" strategy offers speed and efficiency but may trade off the broader investor exposure gained through a traditional, lengthy roadshow process.

To tap into public market investors, Adaptin Bio merged with a 'Form 10' public shell company. This distinct route is not a SPAC as it doesn't raise money in an IPO. Instead, it provides a faster path to becoming a public reporting entity to attract a wider investor base.

The "time is lives" mantra also applies to the companies themselves. For single-asset biotechs with short financial runways, trial delays can bankrupt the company before the drug has a chance. "Time to first patient" is a critical business milestone, not just a clinical one.

When traditional venture funding dried up for Madrigal Pharmaceuticals, they found an unconventional path to capital and a public listing. They pursued a reverse merger with Cinta, a public company that had recently failed a Phase 3 trial and was seeking an exit. This "bake off" victory secured Madrigal $41 million.